For this particular study, the 177Lu-labeled nanobody was developed as an alternative radioimmunotherapy treatment of HER2-positive breast cancers, as some cancers showed signs of resistance towards traditional anti-HER2 monoclonal antibodies such as Trastuzumab. This evidence concerns the gene ERBB2 and cancer.